vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and CIVISTA BANCSHARES, INC. (CIVB). Click either name above to swap in a different company.
CIVISTA BANCSHARES, INC. is the larger business by last-quarter revenue ($47.3M vs $44.9M, roughly 1.1× AbCellera Biologics Inc.). CIVISTA BANCSHARES, INC. runs the higher net margin — 31.7% vs -19.9%, a 51.7% gap on every dollar of revenue. Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 11.3%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Civista Bancshares, Inc. is a US-based bank holding company operating primarily across the Midwest region. It provides a full suite of personal and commercial banking services including deposit accounts, mortgage, consumer and commercial lending products, as well as wealth management solutions, serving retail consumers, small and medium-sized local businesses and community client segments.
ABCL vs CIVB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $47.3M |
| Net Profit | $-8.9M | $15.0M |
| Gross Margin | — | — |
| Operating Margin | -63.7% | — |
| Net Margin | -19.9% | 31.7% |
| Revenue YoY | 788.4% | — |
| Net Profit YoY | 73.9% | 47.4% |
| EPS (diluted) | $-0.03 | $0.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $47.3M | ||
| Q4 25 | $44.9M | $46.3M | ||
| Q3 25 | $9.0M | $44.2M | ||
| Q2 25 | $17.1M | $41.4M | ||
| Q1 25 | $4.2M | $40.6M | ||
| Q4 24 | $5.0M | $40.4M | ||
| Q3 24 | $6.5M | $39.3M | ||
| Q2 24 | $7.3M | $38.1M |
| Q1 26 | — | $15.0M | ||
| Q4 25 | $-8.9M | — | ||
| Q3 25 | $-57.1M | $12.8M | ||
| Q2 25 | $-34.7M | $11.0M | ||
| Q1 25 | $-45.6M | $10.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-51.1M | $8.4M | ||
| Q2 24 | $-36.9M | $7.1M |
| Q1 26 | — | — | ||
| Q4 25 | -63.7% | 31.8% | ||
| Q3 25 | -851.8% | 35.4% | ||
| Q2 25 | -290.2% | 31.1% | ||
| Q1 25 | -1479.6% | 29.4% | ||
| Q4 24 | — | 28.2% | ||
| Q3 24 | -1439.4% | 25.2% | ||
| Q2 24 | -1276.2% | 21.2% |
| Q1 26 | — | 31.7% | ||
| Q4 25 | -19.9% | — | ||
| Q3 25 | -637.8% | 28.9% | ||
| Q2 25 | -203.3% | 26.6% | ||
| Q1 25 | -1077.2% | 25.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | -785.4% | 21.3% | ||
| Q2 24 | -504.3% | 18.5% |
| Q1 26 | — | $0.72 | ||
| Q4 25 | $-0.03 | $0.59 | ||
| Q3 25 | $-0.19 | $0.68 | ||
| Q2 25 | $-0.12 | $0.71 | ||
| Q1 25 | $-0.15 | $0.66 | ||
| Q4 24 | — | $0.62 | ||
| Q3 24 | $-0.17 | $0.53 | ||
| Q2 24 | $-0.13 | $0.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $553.9M |
| Total Assets | $1.4B | $4.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $128.5M | — | ||
| Q3 25 | $83.2M | — | ||
| Q2 25 | $92.4M | — | ||
| Q1 25 | $159.3M | — | ||
| Q4 24 | $156.3M | — | ||
| Q3 24 | $126.6M | — | ||
| Q2 24 | $148.3M | — |
| Q1 26 | — | $553.9M | ||
| Q4 25 | $966.9M | $543.5M | ||
| Q3 25 | $964.0M | $499.0M | ||
| Q2 25 | $1.0B | $404.1M | ||
| Q1 25 | $1.0B | $397.4M | ||
| Q4 24 | $1.1B | $388.5M | ||
| Q3 24 | $1.1B | $394.4M | ||
| Q2 24 | $1.1B | $373.8M |
| Q1 26 | — | $4.3B | ||
| Q4 25 | $1.4B | $4.3B | ||
| Q3 25 | $1.4B | $4.1B | ||
| Q2 25 | $1.4B | $4.2B | ||
| Q1 25 | $1.3B | $4.1B | ||
| Q4 24 | $1.4B | $4.1B | ||
| Q3 24 | $1.4B | $4.1B | ||
| Q2 24 | $1.4B | $4.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | — |
| Free Cash FlowOCF − Capex | $-44.6M | — |
| FCF MarginFCF / Revenue | -99.4% | — |
| Capex IntensityCapex / Revenue | 21.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-34.7M | $43.3M | ||
| Q3 25 | $-52.6M | $19.0M | ||
| Q2 25 | $-32.4M | $11.1M | ||
| Q1 25 | $-11.6M | $3.6M | ||
| Q4 24 | $-108.6M | $48.2M | ||
| Q3 24 | $-28.9M | $12.9M | ||
| Q2 24 | $-30.0M | $12.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-44.6M | $42.1M | ||
| Q3 25 | $-61.5M | — | ||
| Q2 25 | $-45.8M | — | ||
| Q1 25 | $-22.2M | $3.5M | ||
| Q4 24 | $-187.0M | $44.1M | ||
| Q3 24 | $-47.4M | — | ||
| Q2 24 | $-50.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | -99.4% | 90.9% | ||
| Q3 25 | -687.0% | — | ||
| Q2 25 | -267.9% | — | ||
| Q1 25 | -524.0% | 8.5% | ||
| Q4 24 | -3702.8% | 109.1% | ||
| Q3 24 | -728.4% | — | ||
| Q2 24 | -683.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | 21.9% | 2.5% | ||
| Q3 25 | 99.7% | — | ||
| Q2 25 | 78.2% | — | ||
| Q1 25 | 251.1% | 0.4% | ||
| Q4 24 | 1552.7% | 10.4% | ||
| Q3 24 | 284.6% | — | ||
| Q2 24 | 274.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.49× | ||
| Q2 25 | — | 1.01× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 1.73× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABCL
Segment breakdown not available.
CIVB
| Net Interest Income | $37.8M | 80% |
| Noninterest Income | $9.4M | 20% |
